Affymax (Affymax) EBIT per Share : $0.07 (TTM As of Jun. 2014)

View and export this data going back to 2006. Start your Free Trial

What is Affymax EBIT per Share?

Affymax's EBIT per Share for the three months ended in Jun. 2014 was $0.19. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2014 was $0.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Affymax's EBIT per Share or its related term are showing as below:

AFFY's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Affymax's EBIT for the three months ended in Jun. 2014 was $7.21 Mil.

Affymax EBIT per Share Historical Data

The historical data trend for Affymax's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax EBIT per Share Chart

Affymax Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

EBIT per Share

Get a 7-Day Free Trial

-4.13

-0.57

-1.84

-2.53

-0.40

Affymax Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
EBIT per Share	Get a 7-Day Free Trial															0.38	-0.05	-0.04	-0.04	0.19

Affymax EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Affymax's EBIT per Share for the fiscal year that ended in Dec. 2013 is calculated as

	EBIT per Share		(A: Dec. 2013 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-15.017	/	37.448
=	-0.40

Affymax's EBIT per Share for the quarter that ended in Jun. 2014 is calculated as

	EBIT per Share		(Q: Jun. 2014 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	7.209	/	37.490
=	0.19

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07

Affymax (OTCPK:AFFY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Affymax EBIT per Share Related Terms

Thank you for viewing the detailed overview of Affymax's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Executives

John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson	officer: Chief Financial Officer	8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp	officer: Chief Commercial Officer	4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte	director
Karin L Walker	officer: VP, Finance & CAO	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton	director
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland	officer: EVP, Corp. Development and CFO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris	director, officer: CEO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009